Patents by Inventor Kapil Mehta

Kapil Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190105287
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 30, 2018
    Publication date: April 11, 2019
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal
  • Patent number: 10182997
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analog encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analog is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: January 22, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Aggarwal
  • Publication number: 20180318217
    Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.
    Type: Application
    Filed: June 13, 2018
    Publication date: November 8, 2018
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal, Lawrence Helson
  • Patent number: 10004687
    Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: June 26, 2018
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SIGNPATH PHARMA INC.
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
  • Publication number: 20160193159
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 14, 2016
    Publication date: July 7, 2016
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Aggarwal
  • Patent number: 9283185
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: March 15, 2016
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal
  • Publication number: 20140322303
    Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.
    Type: Application
    Filed: May 13, 2014
    Publication date: October 30, 2014
    Applicants: Board of Regents, The University of Texas System, SignPath Pharma Inc.
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
  • Patent number: 8784881
    Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.
    Type: Grant
    Filed: December 1, 2007
    Date of Patent: July 22, 2014
    Assignees: Board of Regents, The University of Texas System, SignPath Pharma Inc.
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
  • Patent number: 8765797
    Abstract: Methods and compounds for treating cancer, dmg resistance and/or metastasis are described herein. These methods and compounds can inhibit the expression of aberrant TG2 expression and/or inhibit the binding of GTP to TG2, and thereby prevent the induction of epithelial to mesenchymal transition of cancer cells, and a stem cell-like phenotype.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: July 1, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kapil Mehta, Anupam Kumar, Jansina Fok, Shuxing Zhang
  • Publication number: 20130158087
    Abstract: Methods and compounds for treating cancer, dmg resistance and/or metastasis are described herein. These methods and compounds can inhibit the expression of aberrant TG2 expression and/or inhibit the binding of GTP to TG2, and thereby prevent the induction of epithelial to mesenchymal transition of cancer cells, and a stem cell-like phenotype.
    Type: Application
    Filed: June 21, 2011
    Publication date: June 20, 2013
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Kapil Mehta, Anupam Kumar, Jansina Fok, Shuxing Zhang
  • Patent number: 8299040
    Abstract: A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: October 30, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kapil Mehta, Amit Verma, Sushovan Guha, Jansina Fok, Gabriel Lopez-Berestein, Anil Sood
  • Publication number: 20110287085
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 27, 2011
    Publication date: November 24, 2011
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat B. Aggarwal
  • Patent number: 7968115
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: June 28, 2011
    Assignee: Board of Regents, The University of Texas System
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal
  • Publication number: 20080279844
    Abstract: A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).
    Type: Application
    Filed: October 5, 2007
    Publication date: November 13, 2008
    Inventors: Kapil Mehta, Amit Verma
  • Publication number: 20080138400
    Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.
    Type: Application
    Filed: December 1, 2007
    Publication date: June 12, 2008
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: RAZELLE KURZROCK, LAN LI, KAPIL MEHTA, BHARAT BHUSHAN AGGARAWAL, LAWRENCE HELSON
  • Publication number: 20080103213
    Abstract: The present invention provides a compositions and methods for the treatment of Neurofibromatosis Type 1 and 2, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system to target Merlin and proteins of the Merlin pathway. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 5, 2007
    Publication date: May 1, 2008
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: RAZELLE KURZROCK, LAN LI, KAPIL MEHTA, BHARAT AGGARWAL
  • Patent number: 7223397
    Abstract: The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: May 29, 2007
    Assignee: Research Development Foundation
    Inventors: Michael Rosenblum, Kapil Mehta
  • Publication number: 20060067998
    Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 7, 2005
    Publication date: March 30, 2006
    Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Aggarawal
  • Patent number: 6414115
    Abstract: The present invention relates to parasitic nematode transglutaminase proteins; to parasitic nematode transglutaminase nucleic acid molecules, including those that encode such transglutaminase proteins; to antibodies raised against such transglutaminase proteins; and to compounds that inhibit parasitic nematode transglutaminase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic nematodes.
    Type: Grant
    Filed: January 13, 1998
    Date of Patent: July 2, 2002
    Assignees: Heska Corporation, Board of Regents, The University of Texas System
    Inventors: Ramaswamy Chandrashekar, Kapil Mehta
  • Patent number: 6334999
    Abstract: To optimize the delivery of all-trans retinoic acid to lung tissue, the potential of vehiculating this drug in liposomes and delivering it via aerosol was determined. Liposomes provide a means to prevent local irritation of lung tissue, reduce pulmonary toxicity, prolong therapeutic levels, and generate high drug concentrations at the tumor sites. Therefore, the delivery of ATRA to the lung tissue in mice was accomplished by nebulization of L-ATRA. The liposomes in the aerosol were uniform, stable, and retained the drug well. The drug was effectively delivered at high concentrations to the lungs of mice and was retained at least up to 96 h after a single exposure to L-ATRA aerosols. The aerosol-delivered ATRA was biologically active as demonstrated by its ability to induce the expression of tissue-type transglutaminase. Aerosol delivery of L-ATRA offers an effective way to deliver high levels of ATRA to the lung without apparent pulmonary toxic effects.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: January 1, 2002
    Assignee: Research Development Foundation
    Inventors: Brian E. Gilbert, Ranjani Parthasarathy, Kapil Mehta